Acute lymphoblastic leukemia (ALL), also known as acute lymphoid leukemia or cancer of the white blood cells, develops from lymphocytes overproduced in the bone marrow that spread to other sites. Survival in ALL has improved in recent decades, owing mostly to combination chemotherapy, preventive CNS-directed therapy, improved risk stratification based on cytogenic features, and early response. In the last few years, several agents have launched that may improve treatment outcomes for patients with ALL, including monoclonal antibodies to CD19 (blinatumomab, Amgen’s Blincyto) and CD20 (Roche/Genentech’s rituximab, [Rituxan]); new drugs for T-cell ALL, such as nelarabine (Novartis’s Arranon/Atriance); and the TKI agents imatinib (Novartis’s Gleevec/Glivec), dasatinib (Bristol-Myers Squibb’s Sprycel), and ponatinib (Ariad Pharmaceuticals’ Iclusig) for the treatment of Ph+ ALL. Nonetheless, chemotherapy remains the backbone of first-line ALL treatment. Therapies in development include immunomodulatory agents, which hold great promise of fulfilling the need for more-effective therapies for this indication.
Questions Answered in This Report:
- Incident cases of ALL are expected to remain relatively stable during our forecast period (2014-2024), although slight growth will occur in the adult population. What is the size of the U.S. and EU5 ALL patient populations, and how will it change over a ten-year period? What are the drug-treatable populations of commercial interest? What is the current medical practice and management for ALL in the markets under study? How does treatment differ by population?
- Several drug classes are in clinical development for ALL, including CAR T-cell therapies, monoclonal antibodies, kinase inhibitors, and re-formulations of existing chemotherapies. What are the key emerging therapies in development for ALL? Which therapies does Decision Resources Group anticipate a launch for, and when? How do key opinion leaders anticipate that these agents, if at all, will be incorporated into the ALL treatment algorithm?
- A high level of unmet need exists in ALL for several key populations. What are the key unmet needs in treatment of ALL and which needs will be addressed by the end of our forecast period? Drug treatment of ALL remains centered around chemotherapy, leaving unmet need opportunities for drug development. What are the main development opportunities?
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Eight country-specific interviews with thought leaders (medical oncologists and hematologists).
Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.
Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.
Emerging therapies: Phase III: 5 drugs; Phase II: 8 drugs.